Total Payments
$158,030
2024 Payments
$4,565
Companies
13
Transactions
235
Medicare Patients
25,039
Medicare Billing
$16.0M
Payment Breakdown by Category
Other$114,847 (72.7%)
Travel$16,677 (10.6%)
Research$13,135 (8.3%)
Food & Beverage$8,071 (5.1%)
Consulting$5,300 (3.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $110,650 | 24 | 70.0% |
| Travel and Lodging | $16,677 | 28 | 10.6% |
| Unspecified | $13,135 | 9 | 8.3% |
| Food and Beverage | $8,071 | 166 | 5.1% |
| Consulting Fee | $5,300 | 1 | 3.4% |
| Current or prospective ownership or investment interest | $2,997 | 6 | 1.9% |
| Honoraria | $1,200 | 1 | 0.8% |
Payments by Type
General
$144,895
226 transactions
Research
$13,135
1 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $136,872 | 108 | $0 (2024) |
| Allergan, Inc. | $13,197 | 4 | $0 (2021) |
| US Retina LLC | $2,997 | 14 | $0 (2024) |
| Alimera Sciences, Inc. | $1,440 | 11 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $1,378 | 56 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $521.84 | 2 | $0 (2022) |
| Apellis Pharmaceuticals, Inc. | $446.43 | 9 | $0 (2024) |
| ABBVIE INC. | $422.46 | 16 | $0 (2024) |
| Astellas Pharma US Inc | $271.53 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $161.41 | 5 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,565 | 33 | Genentech USA, Inc. ($3,712) |
| 2023 | $26,150 | 48 | Genentech USA, Inc. ($23,920) |
| 2022 | $15,755 | 32 | Genentech USA, Inc. ($13,635) |
| 2021 | $1,179 | 12 | US Retina LLC ($999.97) |
| 2020 | $613.18 | 10 | US Retina LLC ($361.14) |
| 2019 | $22,979 | 35 | Genentech USA, Inc. ($22,121) |
| 2018 | $28,109 | 28 | Genentech USA, Inc. ($28,046) |
| 2017 | $58,679 | 37 | Genentech USA, Inc. ($45,341) |
All Payment Transactions
235 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,530.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $109.14 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $98.48 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: Ophthalmology | ||||||
| 11/05/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/29/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $34.15 | General |
| Category: Ophthalmology | ||||||
| 10/23/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/22/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.19 | General |
| Category: EYE CARE | ||||||
| 09/18/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $36.78 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/18/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $0.62 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/10/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: Ophthalmology | ||||||
| 08/15/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: EYE CARE | ||||||
| 08/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/06/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/25/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $33.57 | General |
| Category: EYE CARE | ||||||
| 05/23/2024 | Rayner Intraocular Lenses Limited | RayOne EMV (Device), RayOne Spheric, RayOne Aspheric | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Ophthalmology | ||||||
| 05/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $37.07 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/15/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $27.14 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/07/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 04/30/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.78 | General |
| Category: Ophthalmology | ||||||
| 04/30/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $32.89 | General |
| Category: Ophthalmology | ||||||
| 04/23/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: EYE CARE | ||||||
| 04/03/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 03/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: OPHTHALMOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration | Allergan Inc. | $13,135 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 6,317 | 75,426 | $8.5M | $4.4M |
| 2022 | 18 | 6,497 | 25,461 | $6.2M | $3.9M |
| 2021 | 18 | 6,406 | 20,326 | $6.3M | $3.9M |
| 2020 | 17 | 5,819 | 19,559 | $5.9M | $3.7M |
Total Patients
25,039
Total Services
140,772
Medicare Billing
$16.0M
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 282 | 2,660 | $2.9M | $1.8M | 64.2% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 190 | 58,740 | $2.6M | $1.7M | 65.3% |
| 67028 | Injection of drug into eye | Office | 2023 | 519 | 2,793 | $1.9M | $254,176 | 13.2% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,239 | 1,806 | $277,267 | $164,268 | 59.2% |
| 92134 | Imaging of retina | Office | 2023 | 1,462 | 4,296 | $265,406 | $129,732 | 48.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 36 | 704 | $206,351 | $127,655 | 61.9% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 677 | 1,179 | $129,305 | $78,333 | 60.6% |
| 92250 | Photography of the retina | Office | 2023 | 790 | 1,187 | $54,284 | $34,299 | 63.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 194 | 194 | $40,428 | $25,000 | 61.8% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 103 | 379 | $94,750 | $24,445 | 25.8% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 480 | 1,028 | $19,537 | $12,154 | 62.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 216 | 323 | $19,793 | $11,954 | 60.4% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 42 | 42 | $7,000 | $4,481 | 64.0% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 46 | 46 | $8,344 | $4,277 | 51.3% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 41 | 49 | $1,484 | $932.88 | 62.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 358 | 3,676 | $4.0M | $2.6M | 65.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 57 | 1,280 | $452,505 | $287,418 | 63.5% |
| 67028 | Injection of drug into eye | Office | 2022 | 551 | 2,917 | $417,817 | $263,155 | 63.0% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 55 | 6,360 | $290,525 | $189,791 | 65.3% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 1,193 | 1,778 | $277,261 | $161,914 | 58.4% |
| 92134 | Imaging of retina | Office | 2022 | 1,455 | 4,286 | $214,986 | $129,740 | 60.3% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 724 | 1,572 | $173,392 | $100,189 | 57.8% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 142 | 445 | $111,250 | $29,707 | 26.7% |
| 92250 | Photography of the retina | Office | 2022 | 643 | 966 | $44,446 | $27,991 | 63.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 212 | 212 | $44,974 | $25,831 | 57.4% |
About Dr. Paul Gallogly, MD
Dr. Paul Gallogly, MD is a Ophthalmology healthcare provider based in Palm Beach Gardens, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477500791.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Gallogly, MD has received a total of $158,030 in payments from pharmaceutical and medical device companies, with $4,565 received in 2024. These payments were reported across 235 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($110,650).
As a Medicare-enrolled provider, Gallogly has provided services to 25,039 Medicare beneficiaries, totaling 140,772 services with total Medicare billing of $16.0M. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Palm Beach Gardens, FL
- Active Since 05/30/2006
- Last Updated 11/30/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1477500791
Products in Payments
- Lucentis (Biological) $95,522
- Vabysmo (Drug) $27,632
- VABYSMO (Drug) $13,613
- ILUVIEN (Drug) $1,371
- EYLEA (Biological) $862.10
- OZURDEX (Drug) $484.37
- Syfovre (Drug) $404.88
- DEXYCU (Drug) $362.40
- EYLEA HD (Biological) $268.47
- EYLEA AFLIBERCEPT INJECTION (Biological) $247.07
- Izervay (Drug) $243.13
- YUTIQ (Drug) $228.50
- RayOne EMV (Device) $124.99
- Hydrus (Device) $99.20
- ACTHAR (Biological) $98.48
- SUSVIMO (Drug) $45.25
- BEOVU (Drug) $36.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Palm Beach Gardens
Mark Milner, Md, MD
Ophthalmology — Payments: $1.3M
Ophthalmology $1.3M
Dr. Jorge Fortun, Md, MD
Ophthalmology — Payments: $715,427
Ophthalmology $715,427
Dr. David Goldman, Md, MD
Ophthalmology — Payments: $299,320
Ophthalmology $299,320
Dr. Clifford Salinger, M.d, M.D
Ophthalmology — Payments: $254,530
Ophthalmology $254,530
Larissa Camejo, Md, MD
Ophthalmology — Payments: $221,057
Ophthalmology $221,057
Dr. Mark Kontos, Md, MD
Ophthalmology — Payments: $205,074
Ophthalmology $205,074